Senate Approves FDA Chief; Frist Ends 'Holds' That Long Stalled Vote on Von Eschenbach From: The Washington Post | Date: December 8, 2006| Author: Christopher Lee - Washington Post Staff Writer | Copyright 2006 The Washington Post. This material is published under license from the Washington Post.  All inquiries regarding rights should be directed to the Washington Post.Copyright information

The Senate broke with tradition yesterday in clearing a path for Andrew C. von Eschenbach to become commissioner of the Food and Drug Administration despite attempts by two lawmakers to block the final vote.

In one of his last official acts, retiring Majority Leader Bill Frist (R-Tenn.) forced a procedural vote that ended debate and set up the 80 to 11 approval of von Eschenbach. In doing so, Frist swept aside "holds" by fellow Republicans Charles E. Grassley (Iowa) and David Vitter (L...

Related newspaper, magazine, and journal articles from HighBeam Research

	Senators Prod FDA Nominee On Politicization of Agency The Washington Post ; Acting Food and Drug Administration Commissioner Andrew C. von Eschenbach struggled yesterday to convince a Senate committee that he deserves to lead the agency on a permanent basis, but his efforts were repeatedly undercut by tough questions about the agency's flagging reputation and its
	Bush picks acting FDA head to take over as agency chief: Democrats oppose von Eschenbach over contraceptive's lack of availability. Baltimore Sun (Baltimore, MD) ; Byline: Jonathan D. Rockoff Mar. 16--WASHINGTON--President Bush nominated Dr. Andrew C. von Eschenbach, acting chief of the Food and Drug Administration, to lead the agency, but Democrats immediately moved to block the choice because of the administration's refusal to approve over-the-counter sales
	Acting no longer, von Eschenbach tackles backlog.(NEWS)(Andrew Von Eschenbach) Medical Marketing & Media ; ANDREW VON Eschenbach and the FDA are keeping quiet about the commissioner's formal priorities until he is sworn in this month, but his agenda is likely to correspond closely with that articulated in the Institute of Medicine (IOM) report of 2006. The report was commissioned by FDA to take a hard
	Defining von Eschenbach's Role Pharmaceutical Executive ; AT THE AGENCY The acting commissioner wants FDA to focus on science, but tight funds and Plan B politics could derail his plan. At a recent meeting of PDA's Science Board, Acting Commissioner Andrew von Eschenbach said he doesn't want to be "a simple caretaker" and operate "in a holding pattern" in
	FDA signals Plan B move: Agency says it might allow the sale of morning-after pill over the counter. Baltimore Sun (Baltimore, MD) ; Byline: Jonathan D. Rockoff Aug. 1--WASHINGTON--In a surprise move on the eve of confirmation hearings for a permanent commissioner, the Food and Drug Administration said yesterday that it might soon allow sales of the morning-after pill to some women without a prescription. Dr. Andrew C. von

See all results.